Page 2 - Glenmark Pharmaceuticals

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Why Nomura continues to back Glenmark Pharma; Retains 'Buy'; Find out here

Analysts at Nomura continue to back Glenmark Pharma, citing the company's ability to strategically acquire high-potential innovative products.

Glenmark Pharma signs $18 mn deal with Hengrui for cancer therapy drug

The agreement gives Glenmark exclusive rights to develop and commercialise cancer drug Trastuzumab Rezetecan outside China, the US, Europe, and other select markets

Glenmark gains 3% on $700 mn upfront payment from AbbVie licensing deal

Glenmark shares rose 3% after confirming receipt of $700 million from AbbVie under a global licensing deal for ISB 2001, with milestone payments of up to $1.2 billion

Glenmark Pharma shares rise as arm receives an upfront payment of $700 mn

The buying on the counter came after the company's subsidiary Ichnos Glenmark Innovation received an upfront payment of $700 million from AbbVie

Glenmark starts multi-nation Phase 3 clinical trials for lung cancer drug

Glenmark Pharmaceuticals on Friday said it has initiated a multi-country Phase 3 clinical trial for Envafolimab, a novel drug for third-stage non-small cell lung cancer. The company said it has received approval from the Drugs Controller General of India to begin patient enrolment and dosing in the country. In parallel, the drug firm has submitted a clinical trial application in Russia and is preparing to open additional clinical trial sites in Brazil and Mexico, Glenmark said in a statement. The randomised, multi-centre, Phase 3 trial will assess the efficacy, safety, pharmacokinetics, and immunogenicity of Envafolimab in patients with third-stage non-small cell lung cancer (NSCLC). Lung cancer remains the leading cause of cancer-related deaths worldwide, with NSCLC comprising around 80-85 per cent of cases. "By advancing this trial across multiple geographies, we are reinforcing our commitment to transforming the standard of care in Stage III NSCLC and addressing one of the grea

Glenmark Pharma up 3% on DCGI nod to start phase 3 trial of Envafolimab

Around 11:20 PM, Glenmark Pharmaceuticals shares continued to trade higher, up 3.05 per cent at ₹2,051.40 per share. In comparison, BSE Sensex was trading 0.25 per cent lower at 80,518.51 levels.

These three stocks are a must-have in your portfolio; top reasons here

Markets edged higher and gained over half a percent, supported by optimism surrounding the GST Council meeting.

Don't miss out on these 2 stocks, say analysts at MOFSL; details inside

Recently Nykaa stock had given a breakout on the weekly charts with high volumes. In last few days the stock gradually moved higher and showed relative strength when the markets were correcting.

Glenmark Pharma falls 5% in 2 days on Q1 show; Here's what analysts suggest

Glenmark Pharma stock has tanked over 5 per cent after the company reported lower-than-expected performance in the June 2025 quarter, missing market estimates

Glenmark, Alembic Pharma, Sun Pharma recall drugs in US, says USFDA

Drug makers Glenmark, Alembic Pharmaceuticals and Sun Pharma are recalling products in the US due to manufacturing issues, according to the US health regulator. Mumbai-based Glenmark is recalling two products in the market, the US Food and Drug Administration (USFDA) said in its latest Enforcement Report. Glenmark Pharmaceuticals Inc, USA, a subsidiary of the company, is recalling Carvedilol tablets, used to treat heart failure, hypertension, and heart attack, in multiple strengths. The New Jersey-based firm is recalling 55,560 units of the affected lot due to "presence of a nitrosamine, N-Nitroso Carvedilol impurity above the current acceptable intake level," the USFDA stated. The company is also recalling 17,496 bottles of Carvedilol tablets as "results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm," it added. Glenmark initiated the Class II recall in August this year. USFDA said the company is also recalling 2

Glenmark Pharma Q1 results: Profit falls 86% to ₹47 cr, revenue down 5%

Gelnmark's India revenue stood at ₹1,239.9 crore, up 3.7 per cent Y-o-Y from ₹1,196.2 crore, driven by growth in cardiac, respiratory, and dermatology segments despite weakness in diabetes portfolio

Glenmark, Laurus: 4 pharma stocks gain up to 79% in 5 months; time to exit?

The daily RSI, a key momentum indicator, shows that these 4 pharma stocks namely - Gland Pharma, Glenmark, Biocon and Laurus Labs are trading in the overbought territory; here's what to expect next.

Stocks to Watch today, July 14: VIP Industries, Adani Green, NCC, DMart

Stocks to Watch today, July 14, 2025: Glenmark Pharma, Avenue Supermarts, RVNL and NCC are some of the top stocks to watch today

Near-term upsides from deal with AbbVie may be priced in Glenmark's stock

Glenmark's $700 million deal with AbbVie for ISB-2001 could unlock significant upside, though analysts note the potential is already priced in, with stock surging post-announcement

Glenmark Pharma soars 10%, hits 52-week high on cancer drug licensing deal

At 09:30 AM, Glenmark Pharma shares were trading at ₹2,094.40, up by 10 per cent on the National Stock Exchange.

Stocks to Watch today, July 11: TCS, IREDA, ZEE, HUL, Tata Steel

Stocks to Watch today, July 11, 2025: TCS, IREDA, Glenmark Pharmaceuticals, HUL and Tata Steel are some of the top stocks to watch today

Glenmark arm inks $700 million licensing deal with US-based AbbVie

IGI Therapeutics, a wholly owned subsidiary of Glenmark, has licensed its cancer and autoimmune drug ISB 2001 to AbbVie for an upfront payment of $700 million

Glenmark Pharma's unit, Abbvie sign global licensing deal for cancer drug

Under the agreement, AbbVie will get exclusive rights to develop, manufacture and commercialize ISB 2001 in North America, Europe, Japan and Greater China

Glenmark hits new high; zooms 37% in 2 months; what's driving pharma stock?

Since June 25, in 12 trading days, the stock has surged 12% after the company launched the lung cancer treatment drug Tevimbra in India, following the approval by the CDSCO.